The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 07, 2020

Filed:

May. 20, 2016
Applicant:

Cedars-sinai Medical Center, Los Angeles, CA (US);

Inventors:

Joshua Breunig, Los Angeles, CA (US);

Moise Danielpour, Los Angeles, CA (US);

Assignee:

Cedars-Sinai Medical Center, Los Angeles, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/50 (2006.01); A61K 38/17 (2006.01); C12N 15/113 (2010.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 38/1709 (2013.01); A61P 35/00 (2018.01); G01N 33/5011 (2013.01); G01N 33/5058 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01);
Abstract

Described herein are composition and methods related to targeting the Nf1-Ras-Ets axis, that when perturbed, is identified as playing a role in initiation and maintenance in glioma. A postnatal, mosaic, autochthonous, glioma model that captures the first hours and days of gliomagenesis in more resolution than conventional genetically engineered mouse models of cancer demonstrates that disruption of the Nf1-Ras pathway in the ventricular zone at multiple signaling nodes uniformly results in rapid neural stem cell depletion, progenitor hyperproliferation, and gliogenic lineage restriction. By abolishing Ets subfamily activity, which is upregulated downstream of Ras, there is block of glioma initiation, thereby providing new therapeutic avenues for targeting glioma.


Find Patent Forward Citations

Loading…